441.a Updates on the management of post transplant anemia
Prof. Mohammad Ghnaimat, Jordan
441.1 Effects and adverse events of hypoxia-inducible factor-prolyl hydroxylase inhibitors administration to kidney transplant recipients at a single center in Japan
Dr. Yoshihiro Itabashi, Japan
441.2 Impact of de novo or worsening of pre-existing valvular heart disease in patients referred to the kidney transplant waitlist – a single centre retrospective cohort study
Dr. Satish Vaarman Jeyabalan, Singapore
441.4 To study the long-term impact of hepatitis C treatment in terms of viral load and liver fibrosis among the renal allograft recipients
Dr. Sana Shadab, India
441.5 Potential of 250 New Nautical Mile Concentric Circle Allocation System for Improving the Donor/Recipient HLA Matching
Mr. Fayeq Jeelani Syed, United States
441.6 Impact of CYP3A5 gene polymorphism on tacrolimus pharmacokinetics in kidney transplant patients in Kazakh population
Dr. Islam Madadov, Kazakhstan
441.7 Polarized HLA class I expression on renal tubules hinders the detection of donor-specific urinary extracellular vesicles
Mr. Liang Wu, Netherlands
441.8 Impact of recipient frailty on infection risk after kidney transplantation